Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria~* Male or female patients ≥ 18 years of age~* Ability and willingness to give written informed consent~* Patients scheduled to receive, on day 1 of their chemotherapy, either: (i) a first cisplatin chemotherapy infusion at a dose of ≥70 mg/m2 (males and females); or (ii) a first infusion of cyclophosphamide at a dose of 500-1500 mg/m2 in combination with either epirubicin at a dose of 60-100 mg/m2 or doxorubicin at a dose of 40-60 mg/m2 (females only)~* Karnofsky performance score ≥ 60%~* Adequate cardiac, hepatic and renal function~  * QTc interval \< 500 ms~ * Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \< 5 x upper limit normal (ULN)~ * Bilirubin \< 5 x ULN~ * Creatinine \< 3 x ULN~* Adequate haematological function~  * Haemoglobin ≥ 8 g/dL~ * White blood count ≥ 3.0 x 109/L~ * Platelet count ≥ 100 x 109/L~* For females of child-bearing potential: ability and willingness to use a highly effective form of contraception (e.g., abstinence from sexual intercourse, surgical sterilisation (of subject or partner) or a double-barrier method of contraception such as either an intra-uterine device (IUD) or an occlusive cap with spermicide, in conjunction with partner's use of a condom) during the study and for a period of at least 48 hours afterwards~Exclusion Criteria~* Patients scheduled to receive, prior to or in the 120 hours after cisplatin or AC, any other chemotherapeutic agent with a high or moderate emetic risk~* Patients who have previously received anti-neoplastic chemotherapy~* Patients scheduled to receive paclitaxel or docetaxel during the first cycle of their chemotherapy~* Patients undergoing abdominal or pelvic irradiation within 48 hours prior to screening or scheduled to receive abdominal or pelvic irradiation between screening and 24 hours after cisplatin or AC administration~* Patients with a known prolactin-dependent tumour (e.g. pituitary gland prolactinoma or confirmed prolactin-dependent breast cancer) or phaeochromocytoma~* Patients with a pre-existing vestibular disorder~* Patients being treated with regular anti-emetic therapy including corticosteroids~* Patients receiving inhaled corticosteroids, unless started more than one month prior to the expected date of study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: OTHER): OND + DEX + FOS followed by oral DEX
- Placebo (Type: PLACEBO_COMPARATOR): OND + APD403 followed by oral PLACEBO
- Low dose APD403 (Type: EXPERIMENTAL): OND + APD403 followed by oral APD403 low dose
- Mid dose APD403 (Type: EXPERIMENTAL): OND + APD403 followed by oral APD403 mid dose
- High dose APD403 (Type: EXPERIMENTAL): OND + APD403 followed by oral APD403 high dose

Based on this trial design, predict the completion outcome and termination type (if applicable).